News & Articles

6/12/2024

Real World TARGET-NASH Analysis Shows High Concordance Between New MASLD Definitions and Prior TARGET-NASH Pragmatic Definitions

6/11/2024

EASL 2024 Research: Presentation by Arun J. Sanyal, MBBS, MD

6/11/2024

EASL 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR

6/11/2024

GLP-1 Use and NASH-CHECK Patient-Reported Outcomes Studies from Target RWE Presented at EASL 2024

6/4/2024

World’s Largest Liver Disease-Focused Registry Surpasses 400,000 Patient Enrollment Milestone

5/17/2024

Real-World Evidence Leader in Inflammatory Bowel Disease, Target RWE, Announces Expanded Footprint with TARGET-GASTRO Registry of 30,000+ Patients At Digestive Disease Week

4/15/2024

AGA Announces New Partnership with Target RWE to Gather Real World Data on Eosinophilic Esophagitis (EoE)

3/8/2024

Patient-Reported Outcomes Data from Longest Running Dermatology Study: TARGET-DERM AA Poster Presented at American Academy of Dermatology (AAD) 2024

1/4/2024

Target RWE Launches Novel Precision Medicine Platform to Undertake Growing Unmet Medical Needs in Liver Disease, Gastroenterology, and Immune-mediated Inflammatory Conditions

12/4/2023

Overcoming Scalability Challenges in Real-World Data Processing for Transformative Patient Care

11/13/2023

Real-World Evidence in Pharmaceutical Drug Development – Faster, Safer and More Relevant?

10/23/2023

Leveraging Real-World Evidence with Analytics: 3 Essential Components to Capture a 360-Degree View of Your Patient Population

11/13/2023

TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment Options

11/10/2023

Target RWE Releases Important Updates on the Cirrhosis Quality Collaborative/TARGET-Liver Disease Partnership with the American Association for the Study of Liver Diseases

9/21/2023

New Eosinophilic Gastrointestinal Disorders (EGIDs) Real World Registry Surpasses 1,000 Patient Milestone

8/23/2023

Target RWE's Cutting-Edge Analytical Solutions Launched to Propel Real-World Evidence Generation

8/22/2023

Target RWE Strengthens Industry Leadership Position with Novel Real World Evidence Approaches Presented at ICPE 2023

6/21/2023

World-Leading Real World Data Registry, TARGET-NASH, Surpasses 7,000+ Enrolled Patients and 500,000+ Months of Patient Follow-Up

6/2/2023

Event Recap Blog: TARGET-NASH Analysis Presented at ISPOR 2023 and Target RWE Leaders Present at PMSA 2023

5/8/2023

Real World Evidence Leader Target RWE Shares Expansion and Update on TARGET-GASTRO Longitudinal Study During Digestive Disease Week 2023

3/30/2023

Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASH

3/8/2023

Ewa Kleczyk, PhD Featured on CIO Views Cover for March – A Memento to Women’s History Month & International Women’s Day

2/28/2023

Longest Running Real World Dermatology Registry, TARGET-DERM, Offers Deep Insight into Complex Diseases

1/11/2023

Target RWE Launches 35 New Disease State Registries in Complex Indications with High Unmet Medical Needs and Rapidly Evolving Therapies

10/18/2022

Target RWE and the American Association for the Study of Liver Diseases Announce Research Agreement for Cirrhosis Quality Collaborative

8/25/2022

New Approaches for Developing Real-World Evidence Presented by Target RWE at the 2022 International Conference on Pharmacoepidemiology (ICPE)

8/24/2022

Durham-Based Target RWE Grows Data Abstraction, Curation Capabilities with Latest Acquisition

8/23/2022

Target RWE New Brand, Research, and Advanced Real World Evidence Analytics Showcased at International Conference on Pharmacoepidemiology (ICPE) 2022

7/20/2022

Real-World Data Finds High Prevalence of Pruritus (Itching) and Fatigue, Low Levels of Treatment in Primary Biliary Cholangitis Population

6/24/2022

Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022

6/17/2022

Target RWE Leads Industry Discussion of Fusion Designs and Teaching Advanced Epidemiologic Methods at SER 2022

6/10/2022

Blog - 5 Ways to Write Better Code Using the Tenets of Functional Programming

5/22/2022

New Data Presented at DDW 2022 Shows Nearly Two-Fold Risk of Loss of Remission in Ulcerative Colitis Patients Who Had Histologic Inflammation on Baseline Biopsy

5/20/2022

Target RWE’s Allison Chandler Named One of Triangle Business Journal’s “40 Under 40”

4/5/2022

Blog - What’s the risk? Impacts of Parametric Assumptions for Causal Analysis of Time-to-event Outcomes

4/4/2022

Target RWE Primary Biliary Cholangitis (PBC) Encore Data Presented at APASL 2022

3/29/2022

Large Real-World Study Uncovers Higher Prevalence of Non-Alcoholic Fatty Liver Disease Markers, Liver Biopsy, and Cirrhosis in Children

3/8/2022

TARGET-IBD Study Reveals Nearly a Third of Patients with Inflammatory Bowel Disease Did Not Undergo Objective Assessment Prior to Biologic Dose Change, Discontinuation

12/15/2021

Target RWE Dermatology Study Data Shared at 3rd Annual RAD Conference

11/30/2021

Target RWE Appoints Derek Evans as President

11/3/2021

Peer-Reviewed Target RWE Study Finds Wide Variance in Nonalcoholic Steatohepatitis (NASH) Pathology Reporting

10/19/2021

Blog - One Model to Rule Them All: Using a Single Model to Control for Confounding and Informative Censoring

10/11/2021

Target RWE Inflammatory Bowel Disease Research Presented at UEG Week 2021

9/13/2021

Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year’s Meeting

7/1/2021

Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences

6/29/2021

Liver International Publishes Hepatocellular Carcinoma RWE Review

6/22/2021

Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients

6/15/2021

TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart Disease

5/25/2021

Target RWE COVID-19 Data: Real-World Evidence Analysis Shows 3.6% of COVID-19 Hospitalized Patients Discharged Alive Required Readmission

5/23/2021

Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD Population

5/13/2021

Crohn’s & Colitis 360 Publishes Target RWE Inflammatory Bowel Disease Data

3/1/2021

Andrew von Eschenbach, M.D. Joins Target RWE as Senior Advisor

2/22/2021

TARGET-NASH Real-World Study Reveals Two Thirds Of Patients With NAFLD Had No Record Of Liver Biopsy

2/2/2021

Target RWE Shares Weight Loss Data From Ongoing NASH Study

1/15/2021

Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence Platform

12/21/2020

TARGET-HCC Initial Manuscript Published in Hepatology Communications

12/18/2020

Target RWE Virtual Posters at Annual AIBD, RAD Conferences

11/28/2020

TARGET-DERM Objectives Published in BMJ Open

11/13/2020

Target RWE Data Presented at AASLD Virtual Meeting Provides Important Updates for NASH and PBC Communities

10/1/2020

TARGET-DERM Real-World Study Success Leads To Global Site Expansion And New Dermatologic Conditions

9/24/2020

TARGET-NASH Data Publication Finds Nearly One In Five Patients With NAFLD Have Prior Prescription Opioid Use

9/9/2020

Asian Lean Patients With NAFLD Are 53% Less Likely To Have Cirrhosis, Cardiovascular, And Metabolic Diseases - Latest Data Findings Released From TARGET-NASH Study

9/1/2020

EASL 2020: TARGET-NASH Oral Presentation & Abstract Poster Recap

8/28/2020

Target RWE Builds Growing COVID-19 Data Set of 70,000+ Patients, Announces Published Data Findings

8/24/2020

TARGET-NASH Expands to Europe, Enrolls First Participant

8/17/2020

TARGET-DERM Real-World Evidence Study Reaches 1,000 Enrolled Participants

5/7/2020

Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings

4/14/2020

TARGET-NASH Observational Study Reaches 5,000 Enrolled Patients

3/18/2020

COVID-19 Response

3/17/2020

TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry Partnerships

3/13/2020

TARGET PharmaSolutions Launches Real-World Asthma Study

2/20/2020

TARGET-IBD Poster & Oral Presentation at ECCO

2/13/2020

TARGET PharmaSolutions Appoints Neal Bibeau as Chief Executive Officer

11/21/2019

TARGET-IBD Research Receives Presidential Poster Award And Outstanding Presenter Award At 2019 American College Of Gastroenterology Annual Scientific Meeting

8/15/2019

Executive Voice: She keeps the Triangle on target in life sciences

4/3/2019

2019 Women in Business Award!

2/27/2019

TARGET PharmaSolutions to Advance Dermatology Research, including Atopic Dermatitis, through New Collaboration

2/13/2019

TARGET PharmaSolutions Launches TARGET-DERM Real-World Observational Study to Advance the Understanding of Atopic Dermatitis (Eczema) and Other Immune-Mediated Inflammatory Skin Conditions

12/3/2018

TARGET PharmaSolutions Announces Partnership with Bristol Myers Squibb to Advance Inflammatory Bowel Disease (IBD) Research

11/20/2018

TARGET PharmaSolutions to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead Sciences

10/31/2018

TARGET PharmaSolutions Initiates a New Community, TARGET-HBV, to Advance the Understanding of Hepatitis B

1/10/2019

TARGET PharmaSolutions to advance NASH Research through new collaboration

10/20/2017

Why big pharma is partnering with this Chapel Hill data company - Triangle Business Journal

10/19/2017

Boehringer Ingelheim partners with TARGET PharmaSolutions to Progress NASH Research

10/19/2017

Intercept (ICPT) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH

10/12/2017

Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH

8/18/2017

Alumna Meg Powell Talks with Young Innovators about Clinical Trials

8/2/2017

TARGET PharmaSolutions Enrolls First Participant in its Inflammatory Bowel Disease (IBD) Community

4/20/2017

Allergan Partners with TARGET PharmaSolutions to Advance NASH Research

2/2/2017

TARGET PharmaSolutions Novel Clinical Data Model Helps Drug Industry

11/10/2016

TARGET PharmaSolutions Partners with Bristol-Myers Squibb, Offering a New Platform to Collect Real World Data

11/1/2016

Intercept Announces OCALIVA (OBETICHOLIC ACID) Data in PBC to be Presented at the 2016 AASLD Annual Meeting